Warning: The NCBI web site requires JavaScript to function. more...
Recombinant activated factor VIIa for the treatment of bleeding in major abdominal surgery including vascular and urological surgery: a review and meta-analysis of published data.
von Heymann C, Jonas S, Spies C, Wernecke KD, Ziemer S, Janssen D, Koscielny J.
Crit Care. 2008;12(1):R14. Epub 2008 Feb 15. Review.
Related citations
Recombinant factor VIIa in the treatment of postoperative hemorrhage after cardiac surgery.
Raivio P, Suojaranta-Ylinen R, Kuitunen AH.
Ann Thorac Surg. 2005 Jul;80(1):66-71.
Recombinant activated factor VII in cardiac surgery: experience from the Australian and New Zealand Haemostasis Registry.
Dunkley S, Phillips L, McCall P, Brereton J, Lindeman R, Jankelowitz G, Cameron P.
Ann Thorac Surg. 2008 Mar;85(3):836-44.
Use of recombinant activated factor VII concentrate to control postoperative hemorrhage in complex cardiovascular surgery.
Bowman LJ, Uber WE, Stroud MR, Christiansen LR, Lazarchick J, Crumbley AJ 3rd, Kratz JM, Toole JM, Crawford FA Jr, Ikonomidis JS.
Ann Thorac Surg. 2008 May;85(5):1669-76; discussion 1676-7.
[The use of recombinant activated factor VII for blood loss after cardiovascular surgery].
Gong ZY, Gao CQ, Xiao CS, Li BJ, Ma XH, Zhang CM.
Zhonghua Wai Ke Za Zhi. 2008 Oct 1;46(19):1497-501. Chinese.
Off-label use of recombinant factor VIIa for treatment of haemorrhage: results from randomized clinical trials.
Johansson PI.
Vox Sang. 2008 Jul;95(1):1-7. Epub 2008 Apr 23. Review.
Recombinant activated factor VII in cardiac surgery: a meta-analysis.
Zangrillo A, Mizzi A, Biondi-Zoccai G, Bignami E, Calabrò MG, Pappalardo F, Dedola E, Tritapepe L, Marino G, Landoni G.
J Cardiothorac Vasc Anesth. 2009 Feb;23(1):34-40. Epub 2008 Dec 10.
Safe use of recombinant activated factor VIIa for recalcitrant postoperative haemorrhage in cardiac surgery.
Tatoulis J, Theodore S, Meswani M, Wynne R, Hon-Yap C, Powar N.
Interact Cardiovasc Thorac Surg. 2009 Sep;9(3):459-62. Epub 2009 Jun 18.
Single-center experience: use of recombinant factor VIIa for acute life-threatening bleeding in children without congenital hemorrhagic disorder.
Yilmaz D, Karapinar B, Balkan C, Akisü M, Kavakli K.
Pediatr Hematol Oncol. 2008 Jun;25(4):301-11.
Recombinant activated factor VII for refractory bleeding after acute aortic dissection surgery: a propensity score analysis.
Tritapepe L, De Santis V, Vitale D, Nencini C, Pellegrini F, Landoni G, Toscano F, Miraldi F, Pietropaoli P.
Crit Care Med. 2007 Jul;35(7):1685-90.
Recombinant activated factor VII: a solution to refractory haemorrhage in vascular surgery?
Warren OJ, Alcock EM, Choong AM, Leff DR, Van Herzeele I, Darzi AW, Athanasiou T, Cheshire NJ.
Eur J Vasc Endovasc Surg. 2008 Feb;35(2):145-52. Epub 2007 Oct 25. Review.
Effective management of refractory postcardiotomy bleeding with the use of recombinant activated factor VII.
Filsoufi F, Castillo JG, Rahmanian PB, Scurlock C, Fischer G, Adams DH.
Ann Thorac Surg. 2006 Nov;82(5):1779-83.
Safety of rFVIIa in hemodynamically unstable polytrauma patients with traumatic brain injury: post hoc analysis of 30 patients from a prospective, randomized, placebo-controlled, double-blind clinical trial.
Kluger Y, Riou B, Rossaint R, Rizoli SB, Boffard KD, Choong PI, Warren B, Tillinger M.
Crit Care. 2007;11(4):R85.
Recombinant factor VIIa (NovoSeven) as a hemostatic agent after surgery for congenital heart disease.
Razon Y, Erez E, Vidne B, Birk E, Katz J, Tamari H, Dagan O.
Paediatr Anaesth. 2005 Mar;15(3):235-40.
Recombinant factor seven therapy for postoperative bleeding in neonatal and pediatric cardiac surgery.
Agarwal HS, Bennett JE, Churchwell KB, Christian KG, Drinkwater DC Jr, He Y, Taylor MB.
Ann Thorac Surg. 2007 Jul;84(1):161-8.
Recombinant factor VIIa treatment of severe bleeding in cardiac surgery patients: a retrospective analysis of dosing, efficacy, and safety outcomes.
Masud F, Bostan F, Chi E, Pass SE, Samir H, Stuebing K, Liebl MG.
J Cardiothorac Vasc Anesth. 2009 Feb;23(1):28-33. Epub 2008 Oct 22.
[The use of recombinant activated factor VIIa for major bleedings in open heart surgery].
Ingimarsson JP, Onundarson PT, Valsson F, Vidarsson B, Gudbjartsson T.
Laeknabladid. 2008 Sep;94(9):607-12. Icelandic.
Risk of thromboembolic events in controlled trials of rFVIIa in spontaneous intracerebral hemorrhage.
Diringer MN, Skolnick BE, Mayer SA, Steiner T, Davis SM, Brun NC, Broderick JP.
Stroke. 2008 Mar;39(3):850-6. Epub 2008 Jan 31.
Use of recombinant factor VIIa for uncontrolled bleeding in neonates after cardiopulmonary bypass.
Guzzetta NA, Huch S, Fernandez JD, Tosone SR, Miller BE.
Paediatr Anaesth. 2009 Apr;19(4):364-70. Epub 2008 Dec 30.
Thromboembolic adverse events after use of recombinant human coagulation factor VIIa.
O'Connell KA, Wood JJ, Wise RP, Lozier JN, Braun MM.
JAMA. 2006 Jan 18;295(3):293-8.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on